Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-10-04 |
Avrobio (USA - MA) GenStem Therapeutics (USA ) |
AVR-RD-04 |
cystinosis |
licensing |
Rare diseases - Genetic diseases - Lysosomal diseases |
Licensing agreement |
2017-10-04 |
BioNTech (Germany) Eufets (Germany) BioNTech Innovative Manufacturing Services (Germany) |
cell and gene therapy products |
|
establishment of a new subsidiary in the EU |
Technology - Services |
Establishment of a new subsidiary in the EU |
2017-10-03 |
Merck KGaA (Germany) |
new production line at the manufacturing site of Bari |
|
construction of new premises |
|
Construction of new premises |
2017-10-03 |
Lonza (Switzerland) Shire (UK - USA) |
clinical-stage mammalian manufacturing site in Hayward (USA - CA) |
|
plant acquisition |
Technology - Services |
Plant acquisition |
2017-10-03 |
Merck KGaA (Germany) |
Modugno-Bari production site |
|
construction of new premises |
Technology - Services |
Construction of new premises |
2017-10-02 |
Transgene (France) Randox (UK) |
oncolytic immunotherapies using Transgene’sviral platform Invir.IO™ and Randox’s SdAbs (single-domain antibodies)
|
|
development - collaboration |
Cancer - Oncology |
Development agreement |
2017-10-02 |
KSQ Therapeutics (USA - MA) |
chief executive officer - chief scientific officer |
|
nomination |
Cancer - Oncology |
Nomination |
2017-09-29 |
TG Therapeutics (USA - NY) Fast Forward (USA - NY) |
TGR-1202 (umbralisib) |
progressive multiple sclerosi |
clinical research |
Neurodegenerative diseases |
Clinical research agreement |
2017-09-28 |
OSE Immunotherapeutics (France) Inserm Transfert (France) |
cancer immunotherapy targeting a new suppressive myeloid cell receptor (a C-type lectin receptor) |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2017-09-28 |
Basilea Pharmaceutica (Switzerland) China Resources Gosun Pharmaceutical (China) |
Zevtera®/Mabelio® (ceftobiprole) |
severe community-acquired and hospital-acquired pneumonia |
licensing |
Infectious diseases |
Licensing agreement |
2017-09-27 |
Bavarian Nordic (Denmark) U.S. Department of Health & Human Services (HHS - USA) |
Imvamune® smallpox vaccine |
smallpox |
supply - distribution |
Infectious diseases |
Distribution agreement |
2017-09-27 |
Cancer Research UK (CRUK) (UK) Glythera (UK) |
CDK11 inhibitor payload series for the development of antibody drug conjugates |
|
licensing |
Cancer - Oncology |
Licensing agreement |
2017-09-26 |
OSE Immunotherapeutics (France) Selexis (Switzerland) |
research cell banks (RCBs) from the Selexis SUREtechnology Platform™ |
|
services contract |
Technology - Services |
Services contract |
2017-09-26 |
Confo Therapeutics (Belgium) Lundbeck (Denmark) |
small molecule therapeutic compounds acting upon two G-protein
coupled receptors (GPCRs) |
|
research - R&D |
Neurological diseases - Psychiatric diseases |
Research agreement |
2017-09-26 |
Bicycle Therapeutics (UK - USA) |
chief medical officer |
|
nomination |
Cancer - Oncology |
Nomination |
2017-09-25 |
Tapimmune (USA - FL) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-09-21 |
Juno Therapeutics (USA - WA) |
headquarters and research facility |
|
opening of new premises |
Cancer - Oncology |
Opening of new premises |
2017-09-20 |
Enterome Bioscience (France) |
research laboratories in Genopole |
|
opening of new premises |
Autoimmune diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology |
Opening of new premises |
2017-09-20 |
Enterome Bioscience (France) |
|
|
opening of new premises |
Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases |
Opening of new premises |
2017-09-20 |
Synpromics (UK) Solid Biosciences (USA - MA) |
muscle-selective promoter candidates |
Duchenne muscular dystrophy (DMD) |
research - R&D |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Research agreement |